Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Nov;26(11):735-740.
doi: 10.1016/j.annepidem.2016.04.012. Epub 2016 Aug 31.

Challenges in evaluating cancer as a clinical outcome in postapproval studies of drug safety

Simone P Pinheiro  1 , Donna R Rivera  2 , David J Graham  3 , Andrew N Freedman  2 , Jacqueline M Major  3 , Lynne Penberthy  2 , Mark Levenson  4 , Marie C Bradley  5 , Hui-Lee Wong  3 , Rita Ouellet-Hellstrom  3
Affiliations
Review

Challenges in evaluating cancer as a clinical outcome in postapproval studies of drug safety

Simone P Pinheiro et al. Ann Epidemiol. 2016 Nov.

Abstract

Pharmaceuticals approved in the United States are largely not known human carcinogens. However, cancer signals associated with pharmaceuticals may be hypothesized or arise after product approval. There are many study designs that can be used to evaluate cancer as an outcome in the postapproval setting. Because prospective systematic collection of cancer outcomes from a large number of individuals may be lengthy, expensive, and challenging, leveraging data from large existing databases are an integral approach. Such studies have the capability to evaluate the clinical experience of a large number of individuals, yet there are unique methodological challenges involved in their use to evaluate cancer outcomes. To discuss methodological challenges and potential solutions, the Food and Drug Administration and the National Cancer Institute convened a two-day public meeting in 2014. This commentary summarizes the most salient issues discussed at the meeting.

Keywords: Cancer epidemiology; Drug safety; Pharmacoepidemiology.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. US Food and Drug Administration. Methodological considerations in evaluation of cancer as an adverse outcome associated with use of non-biological drugs and biological products in the post-approval setting; public meeting. [accessed 20.12.2014];Presentations, transcripts, agenda background Mater available. Available at: http://www.fda.gov/Drugs/NewsEvents/ucm401452.htm.
    1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. - PubMed
    1. Potter JD. Colorectal cancer: molecules and populations. J Natl Cancer Inst. 1999;91(11):916–32. - PubMed
    1. Stratton MR. Journeys into the genome of cancer cells. EMBO Mol Med. 2013;5(2):169–72. - PMC - PubMed
    1. Chia WK, Ali R, Toh HC. Aspirin as adjuvant therapy for colorectal cancer—reinterpreting paradigms. Nat Rev Clin Oncol. 2012;9(10):561–70. - PubMed

Substances

LinkOut - more resources